COVID-19: A management update

ABSTRACT

The management of COVID-19 has evolved through the course of the pandemic to now include options for outpatients, inpatients with life-threatening critical illness, and everyone in between. The goals of therapy include preventing disease progression and preventing worsening disease in those admitted to the hospital, with the hopes of preserving resources and improving patient outcomes. The Infectious Diseases Society of America and the National Institutes of Health have issued guidelines on treating COVID-19, which the authors review here.

KEY POINTS

- All patients with COVID-19, no matter how mild or severe it is, should self-isolate or be placed in isolation to avoid spreading the disease.

- Nirmatrelvir-ritonavir is recommended for outpatients with mild or moderate COVID-19 who are at risk of progressing to serious disease.

- Remdesivir can be considered in patients with mild to moderate disease who are at high risk for progression to severe COVID-19, and in hospitalized patients with oxygen saturation less than 94% breathing room air, but not in those who already need mechanical ventilation or extracorporeal membrane oxygenation.

- Dexamethasone 6 mg is the standard of care for hospitalized patients with severe or critical COVID-19.

What started as a sprint has become a marathon with no end in sight. At 3 years into the COVID-19 pandemic, the medical community continues to seek answers through research on how to best manage this disease in its spectrum of presentations, and how to translate the answers into evidence-based guidelines. Numerous drugs have been used or considered for use, and as fast as the virus mutated, so did the efficacy and safety of these drugs, as evidenced in trial data.

Treatment recommendations have rapidly evolved and depend on the patient’s medical history, healthcare setting, severity of disease, and other variables. In March 2020, the Infectious Diseases Society of America (IDSA) assembled a multidisciplinary panel to review evidence and make continuing recommendations about treating and managing COVID-19.1 The National Institutes of Health also issued its own guidelines, which are similar but include recommendations for special populations such as those with preexisting medical conditions (including cancer), different age groups, and ethnic groups.2

To date, the IDSA has made 32 recommendations regarding treating COVID-19 (Table 1).3 Many of the recommendations are against using treatments that don’t work, such as hydroxychloroquine. Below, we outline the evidence and recommendations in favor of those that do.

INFECTION CONTROL FOR ALL

The estimated incubation period for COVID-19 is up to 14 days, and the virus is transmissible 2 to 3 days before symptoms start—thus the need for masking and social distancing during outbreaks. Isolation is necessary for all patients with COVID-19.
COVID-19 MANAGEMENT

Most patients experience fever, cough, and shortness of breath.1–3 Like those of many other viral illnesses, these symptoms are nonspecific, and some patients experience atypical symptoms, posing diagnostic challenges.2,4,5

While the numbers have gone up and down,6 as the pandemic grinds through its third year, COVID-19 was responsible for more than 15,000 hospital admissions in the United States in the week of August 13 to August 19, 2023, and for 2.0% of deaths—and these numbers are creeping up at the time of this writing.7 We will need to continue to discover and study the best therapies to mitigate the effects of the pandemic for the foreseeable future.

■ TREATMENTS FOR OUTPATIENTS

Although outpatients with COVID-19 generally have milder disease than those admitted to the hospital, some have risk factors for progressing to severe disease

TABLE 1
Treating COVID-19: 32 recommendations from the Infectious Diseases Society of America

<table>
<thead>
<tr>
<th>Recommended</th>
<th>Not recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone for hospitalized critically ill patients</td>
<td>Hydroxychloroquine</td>
</tr>
<tr>
<td>Dexamethasone for hospitalized patients with severe but noncritical COVID-19</td>
<td>Hydroxychloroquine plus azithromycin for hospitalized patients with COVID-19</td>
</tr>
<tr>
<td>Tocilizumab for hospitalized adults with progressive severe or critical COVID-19 who have elevated markers of systemic inflammation</td>
<td>Hydroxychloroquine for patients exposed to COVID-19</td>
</tr>
<tr>
<td>Sarilumab for patients who would qualify for tocilizumab, if tocilizumab is not available</td>
<td>Lopinavir-ritonavir for patients exposed to COVID-19</td>
</tr>
<tr>
<td>Convalescent plasma for ambulatory patients with mild to moderate COVID-19 at high risk of progressing to severe disease who have no other treatment options, within 8 days of symptom onset</td>
<td>Lopinavir-ritonavir for ambulatory patients with mild to moderate COVID-19</td>
</tr>
<tr>
<td>Remdesivir for patients with mild to moderate COVID-19 within 7 days of symptom onset at high risk of progressing to severe disease</td>
<td>Lopinavir-ritonavir for hospitalized patients</td>
</tr>
<tr>
<td>Remdesivir for 5 days rather than 10 days for patients on supplemental oxygen but not on mechanical ventilation or extracorporeal mechanical ventilation</td>
<td>Glucocorticoids for hospitalized patients with mild to moderate COVID-19 without hypoxemia requiring supplemental oxygen</td>
</tr>
<tr>
<td>Remdesivir for hospitalized patients with severe COVID-19</td>
<td>Inhaled corticosteroids for ambulatory patients with mild to moderate COVID-19</td>
</tr>
<tr>
<td>Baricitinib with corticosteroids for hospitalized adults with severe COVID-19</td>
<td>Convalescent plasma for hospitalized immunocompetent patients</td>
</tr>
<tr>
<td>Baricitinib with remdesivir for hospitalized patients with severe COVID-19 who cannot receive a corticosteroid</td>
<td>Routine use of convalescent plasma for hospitalized immunocompromised patients</td>
</tr>
<tr>
<td>Tofacitinib for hospitalized adults with severe COVID-19 but not on noninvasive or invasive mechanical ventilation</td>
<td>Remdesivir for those on mechanical ventilation, extracorporeal membrane oxygenation, or both</td>
</tr>
<tr>
<td>Fluvoxamine (but only in a clinical trial)</td>
<td>Famotidine for ambulatory patients with mild to moderate COVID-19</td>
</tr>
<tr>
<td>Nirmatrelvir-ritonavir within 5 days of symptom onset in ambulatory patients with mild to moderate COVID-19 at high risk of progressing to severe disease</td>
<td>Famotidine for hospitalized patients with severe COVID-19</td>
</tr>
<tr>
<td>Molnupiravir within 5 days of symptom onset in ambulatory adults with mild to moderate COVID-19 at high risk of progressing</td>
<td>Ivermectin for hospitalized patients</td>
</tr>
<tr>
<td></td>
<td>Ivermectin for ambulatory patients</td>
</tr>
<tr>
<td></td>
<td>Colchicine for hospitalized patients</td>
</tr>
<tr>
<td></td>
<td>Colchicine for ambulatory patients</td>
</tr>
<tr>
<td></td>
<td>Anakinra for hospitalized patients with severe COVID-19</td>
</tr>
</tbody>
</table>

Based on information in reference 1.
It is this group for whom drug treatment is indicated.

**Monoclonal antibodies are not currently available**

SARS-CoV-2, the virus that causes COVID-19, is a ball studded with a “spike” protein, by which it attaches to and merges with the host cell. Early in the pandemic, monoclonal antibodies that target the spike protein were shown to have clinical benefits in treating SARS-CoV-2 infection, and the IDSA recommended them for nonhospitalized patients who had mild to moderate COVID-19 but were at high risk of progression to severe disease or death. Four products received emergency use authorization from the US Food and Drug Administration to treat adult outpatients with mild to moderate COVID-19: bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab, and bebtelovimab. However, the anticipated activity of the different available antibodies varies dramatically depending on the currently circulating COVID-19 variant. The previously authorized antibodies were not expected to be effective against omicron variants of the virus and therefore are not currently authorized for use.

**Outpatient antiviral therapies**

Even if the virus has attached itself to the host cell and has gotten in, all is not lost. We can still try to prevent it from replicating and thereby prevent an infection from progressing to more severe disease that could necessitate hospitalization and cause death in patients at high risk. Safe and effective oral agents that do this could help to reduce ongoing strain on healthcare systems and overwhelmed hospital facilities.

**Nirmatrelvir-ritonavir** is an oral antiviral agent. Nirmatrelvir is a protease inhibitor that targets 3-chymotrypsin-like cysteine protease, an enzyme the virus needs to replicate, whereas ritonavir boosts the activity of nirmatrelvir by inhibiting its metabolism by cytochrome 3A4.

In the Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients (EPIC-HR) trial, the largest clinical trial of nirmatrelvir-ritonavir, patients at high risk who were treated within 3 days of symptom onset had an 89% lower risk of progression to severe critical illness compared with those who received placebo, without any evident safety concerns. The IDSA suggests starting this treatment within 5 days of symptom onset in nonhospitalized patients with mild to moderate COVID-19 at high risk of progression to severe disease.

**Molnupiravir**, another antiviral agent, is approved for outpatient use based on the results of a large clinical trial in unvaccinated patients who had at least 1 risk factor for severe COVID-19 illness and who could not receive nirmatrelvir-ritonavir, remdesivir, or monoclonal antibodies, in which early treatment (within 5 days of symptom onset) with molnupiravir reduced the risk of hospitalization and death.

Nirmatrelvir-ritonavir or molnupiravir should be considered for patients with COVID-19 who are age 65 or older or who are age 12 or older with an underlying condition that increases the risk of severe outcomes of COVID-19. The current recommendations advise against treating patients who have no symptoms or who have symptoms but no high-risk features. There are no recommendations for repeat courses of therapy in patients previously treated with antivirals who experience rebound symptoms.

### TABLE 2

**Risk factors for severe COVID-19 illness**

<table>
<thead>
<tr>
<th>Age &gt; 65, or age &gt; 50 and not vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic lung disease (chronic obstructive pulmonary disease, asthma, interstitial lung disease, pulmonary hypertension, bronchiectasis)</td>
</tr>
<tr>
<td>Cardiovascular disease (heart failure, coronary artery disease, or cardiomyopathy)</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td>Obesity (body mass index &gt; 30 kg/m²)</td>
</tr>
<tr>
<td>Sickle cell disease</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
</tr>
<tr>
<td>Primary immunodeficiency or immunocompromised state from solid-organ transplantation</td>
</tr>
<tr>
<td>Cancer</td>
</tr>
</tbody>
</table>

Based on information in reference 2.
Given the risk of rebound illness, particularly with nirmatrelvir-ritonavir, the decision to treat should not be based solely on the goal of hastening recovery. Rather, the focus should be on mitigating the risk of progression to severe disease. Patients and prescribers should have a shared medical decision-making discussion to clearly outline the goals of therapy and the risks before starting.

Patients being treated with antivirals in the outpatient setting (Table 3) still need to isolate themselves to reduce transmission.

### TREATMENT FOR HOSPITALIZED PATIENTS

While most COVID-19 cases are either asymptomatic or mild, a substantial percentage of patients develop severe respiratory illness requiring hospitalization. Indications for treatment vary depending on severity of illness (Table 4).

#### Remdesivir, an antiviral medication

Remdesivir inhibits viral replication by terminating its RNA transcription, and hopes were high that it would help critically ill patients with COVID-19 who had evidence of hypoxemic respiratory failure. However, 4 main trials of remdesivir in patients with moderate to severe disease found no significant benefit compared with the standard of care in terms of in-hospital mortality. Furthermore, a 2021 study found no clinical benefit from remdesivir in hospitalized patients who had had COVID-19 symptoms for more than 7 days and needed oxygen support. In a more positive direction, in a 2022 trial in patients with COVID-19 spanning the disease spectrum, fewer patients who received remdesivir needed mechanical ventilation compared with those who did not receive the drug.

The IDSA recommends that remdesivir be considered in patients with mild to moderate disease who are at high risk of progression to severe COVID-19 and in hospitalized patients with oxygen saturation less than 94% breathing room air, and that it not be considered in those who already need mechanical ventilation or extracorporeal membrane oxygenation. When used in those with severe or critical illness, it should be considered an adjunct therapy, given in addition to glucocorticoids (see below).

#### Steroids: Dexamethasone 6 mg, the standard of care

COVID-19 is associated with diffuse lung injury through an inflammation-mediated response within the lung parenchyma. It is not the infection itself that causes most of the damage but rather the body’s exaggerated reaction to it—the “cytokine storm.” Glucocorticoids have long been used to modulate inflammation, and several studies have investigated their use in hospitalized patients with COVID-19. The Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial established dexamethasone as the standard of care in patients with COVID-19. Patients were assigned to receive either dexamethasone 6 mg daily for 10 days or usual care alone. Overall, the mortality rate at 28 days was significantly lower with dexamethasone. However, no difference was detected in the subgroup of patients who did not need supplemental oxygen at baseline. This led the IDSA to recommend that dexamethasone be used only in patients with a pulse oximeter reading of less than 94% on room air or in those requiring supplemental oxygen.

Because dexamethasone 6 mg was good, further studies sought to determine if 12 mg would be better. It wasn’t. In a trial in patients hospitalized with...
COVID-19 who needed supplemental oxygen, there was no significant difference in clinical outcomes between the dosing groups, confirming the original dose of 6 mg per day. A more recent study looked at the effects of high-dose vs low-dose dexamethasone therapy on all-cause mortality at 60 days, and at the effect of different oxygenation strategies vs standard of care on the need for invasive mechanical ventilation at 28 days. The findings suggest that neither make any significant difference in these outcomes.

Interleukin 6 inhibitors

To curb the immune response to COVID-19, in addition to giving steroids, experts began looking at agents that inhibit interleukin 6 (IL-6), a cytokine produced by macrophages that induces an inflammatory response and is often elevated in patients with COVID-19. One of the attractions of targeting IL-6 is that approved agents already exist that inhibit either the cytokine itself (anakinra, canakinumab, and rilonacept) or its receptor (tocilizumab and sarilumab). Enthusiasm for these agents was high, although it was unclear whether IL-6 inhibitors were safe in COVID-19, as they make patients more vulnerable to infection.

Several studies of IL-6 inhibitors in hospitalized patients with COVID-19 had positive results and shaped practice: in-hospital mortality was reduced, as was the amount of organ support required. As use in practice continued, further studies looked at another outcome, ie, the patient’s clinical status by day 28 (ranging from discharged to dead), with death as a secondary outcome. Unfortunately, there was minimal difference in either outcome between those receiving tocilizumab vs placebo. Other trials similarly found no profound effect on the mortality rate.

However, in the RECOVERY trial, tocilizumab use was associated with a lower risk of progression to either mechanical ventilation or death (35% vs 42%). This was further supported by a meta-analysis of 27 randomized controlled trials that evaluated IL-6 inhibitors (usually tocilizumab) and found that their use was associated with a lower rate of 28-day all-cause mortality.

Regarding sarilumab, the largest trial of this agent to date included more than 400 patients with COVID-19 who needed supplemental oxygen or intensive care unit admission. This trial found no difference in clinical outcomes with sarilumab vs placebo, and sarilumab is recommended only if tocilizumab is unavailable.

In summary, for hospitalized adults with progressive severe COVID-19 (with low oxygen levels requiring supplemental oxygen) or critical illness (requiring mechanical ventilation or in multiorgan failure) who have elevated markers of systemic inflammation, the IDSA suggests giving tocilizumab in addition to the standard of care (ie, steroids) rather than standard of care alone.

### Table 4

<table>
<thead>
<tr>
<th>Features</th>
<th>Mild or moderate</th>
<th>Severe</th>
<th>Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Oxygen saturation ≥ 94%</td>
<td>Respiratory failure requiring high-flow nasal cannula or noninvasive mechanical ventilation</td>
<td>Respiratory failure requiring invasive mechanical ventilation or extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>Oxygen saturation &lt; 94%</td>
<td>Respiratory rate ≥ 30 breaths/min</td>
<td>Dexamethasone with or without remdesivir</td>
<td></td>
</tr>
<tr>
<td>Lung infiltrates on chest radiography &gt; 50%</td>
<td></td>
<td>Consider an immune modulator</td>
<td></td>
</tr>
</tbody>
</table>

| Isolation | Yes | Yes | Yes | Yes |
| Treatment | Remdesivir | Remdesivir plus dexamethasone | Dexamethasone plus baricitinib, tofacitinib, or tocilizumab |

Based on information in reference 1.
Janus kinase inhibitors

Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, is another agent that inhibits the inflammatory response in viral illness.

COV-BARRIER (Study of Baricitinib [LY3009104] in Participants With COVID-19),24 a randomized, double-blind, placebo-controlled trial, analyzed 1,525 hospitalized patients with COVID-19 in 12 countries who had elevations of 1 or more inflammatory biomarkers. The patients were randomized 1-to-1 to receive a once-daily oral dose of baricitinib 4 mg or placebo in addition to the local standard of care for up to 14 days or until hospital discharge. Standard of care included systemic corticosteroids such as dexamethasone and antivirals such as remdesivir. The trial found no significant reduction in the trajectory of disease progression overall. By day 28, 8% of the patients in the baricitinib group had died compared with 13% in the placebo group, a 38% relative risk reduction. The incidence of serious adverse events, infections, and venous thromboembolic events was similar between the baricitinib group and the placebo group.

In the Adaptive COVID-19 Treatment Trial 2, the combination of baricitinib and remdesivir shortened the time to recovery in hospitalized patients with COVID-19 compared with remdesivir alone. The acceleration to improvement was most pronounced in the patients who were receiving high-flow oxygen or noninvasive ventilation. Of note, when analyzed by severity of disease, the median time to recovery in the noninvasive ventilation or high-flow oxygen delivery group who received combination therapy was 10 days, compared with 18 days in the control group (which was receiving remdesivir alone).25

The recommended dose of baricitinib is 4 mg once a day (adjusted for renal impairment) for up to 14 days or until discharge from the hospital.25

Tofacitinib is another agent of interest in the same class. In the STOP-COVID trial (Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19),26 tofacitinib was associated with a decreased risk of respiratory failure and death. Approximately 80% of participants in each treatment group also received corticosteroids, and thus this trial supports that tofacitinib plus steroids is effective in improving outcomes in hospitalized patients with COVID-19.26 Baricitinib is favored over tofacitinib because it has more data to support its use. However, tofacitinib can be considered if baricitinib is unavailable.26 The IDSA recommends that if tofacitinib is used, it should be in addition to the standard of care for patients hospitalized for severe COVID-19, and that patients should receive at least prophylactic doses of anticoagulants while in the hospital in view of the risk of venous thromboembolism with tofacitinib.1 Moreover, patients who receive Janus kinase inhibitors should not receive tocilizumab or other immunomodulators, owing to inadequate evidence for combined treatment.1,2

In summary, baricitinib and tofacitinib appear to provide the most benefit in those with severe COVID-19 on supplemental or high-flow oxygen support.1

LONG COVID

The COVID-19 pandemic is the biggest public health crisis of the 21st century. In addition to the acute symptoms of active illness, the long-term health complications of COVID-19 pose significant challenges.27

The National Institute for Health and Care Excellence defined post-COVID-19 syndrome (“long COVID”) as “signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis.”28 Up to half—or maybe more—of all COVID-19 survivors experience long COVID symptoms after initial recovery from acute infection. These symptoms include but are not limited to fatigue, muscle pain, palpitations, cognitive impairment, dyspnea, anxiety, chest pain, and arthralgia. About one third of these patients experience these lingering symptoms for about 2 months after their initial infection.29

Currently, no treatments have been shown to prevent the development of or decrease post-COVID-19 syndrome, although trials are ongoing.30

DISCLOSURES

Dr. Sacha has disclosed consulting for Wolters-Kluwer. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.
REFERENCES


Address: Kathryn Bash, MHSc, MSN, APRN-BC, Department of Pulmonary and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; bashk@ccf.org